Company
Annexon Biosciences
Unlocking the next generation of complement therapies
- Business model
- B2B
- Legal name
- Annexon, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
We are focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain and eye.
Funding snapshot
- Total raised
- $278MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $130M2022-07-07
Funding rounds
- Round, 2022
- $130M2022-07-07, SEC form D sold, 12 investors
- Round, 2020
- $102M2020-06-30, SEC form D sold, 17 investors
- Round, 2018
- $45M2018-12-07, SEC form D sold, 10 investors
- Round, 2011
- $1000K2011-08-16, SEC form D sold, 1 investor
Products
- Web
- ANX005
- Web
- ANX007
- Web
- ANX009
- Web
- ANX1502
Loading relationship preview